Agomelatine Treatment of Major Depressive Disorder in Parkinson's Disease: A Case Series

• DOI: 10.1176/appi.neuropsych.12110286
• Publication Date: 2013-11-18T20:02:12Z
• Authors: Domenico De Berardis; Michele Fornaro; Nicola Serroni; Luigi Olivieri; Stefano Marini; Francesco Saverio...; Venkataramanujam ...; Maurizio Assetta; Alessandro Valchera; Anatolia Salone; Giovanni Martinotti; Marco Onofrj; Massimo Di Gianna...
• Keywords: Agomelatine; Depression

Major Depressive Disorder (MDD) is among the most frequent comorbidities occurring in course of Parkinson's disease (PD), and therefore, PD patients receive antidepressant drugs. Agomelatine a recently introduced drug acting as an MT1/MT2 melatonergic receptor agonist 5HT2C/5HT2B serotonergic antagonist. The aim this case series was to evaluate role agomelatine treatment MDD associated with PD.